Credit: Shutterstock photoOrchard Therapeutics, which is developing gene therapies for rare diseases, filed on Thursday with the SEC to raise up to $173 million in an initial public offering.
The London, United Kingdom-based company was founded in 2015 and plans to list on the Nasdaq under the symbol ORTX. Orchard Therapeutics filed confidentially on August 6, 2018. J.P. Morgan, Goldman Sachs and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Heal thyself: Autologous gene therapy biotech Orchard Therapeutics files for a $173 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
